Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Defence Therapeutics Inc
(OP:
DTCFF
)
0.3635
-0.0131 (-3.48%)
Streaming Delayed Price
Updated: 9:52 AM EDT, Jun 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Defence Therapeutics Inc
Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
December 11, 2025
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences; Defence Therapeutics
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
December 09, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
November 14, 2023
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in
Via
PressReach
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
November 07, 2023
(November 7, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge
Via
PressReach
Topics
Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
October 18, 2023
(October 18, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the
Via
PressReach
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...
Via
PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
October 10, 2023
(October 10, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the
Via
PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
September 26, 2023
(September 25, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the
Via
PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
May 10, 2023
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics...
Via
Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
May 04, 2023
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2023) - On FOX Business News broadcast on Sunday, May 7 at 5:30...
Via
Newsfile
Topics
Supply Chain
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
September 29, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Via
Newsfile
Topics
Death
Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
September 21, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Via
Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
September 16, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Via
Newsfile
Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)
October 19, 2021
Via
AB Newswire
Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)
October 12, 2021
Via
AB Newswire
Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)
October 05, 2021
Via
AB Newswire
Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)
September 28, 2021
Via
AB Newswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
